West Pharmaceutical: Q3 Earnings Insights

Shares of West Pharmaceutical Servs WST rose 0.3% in pre-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share increased 45.57% over the past year to $1.15, which beat the estimate of $0.99.

Revenue of $548,000,000 rose by 20.15% from the same period last year, which beat the estimate of $510,140,000.

Looking Ahead

The upcoming fiscal year's EPS expected to be between $4.50 and $4.55.

The upcoming fiscal year's revenue expected to be between $2,100,000,000 and $2,110,000,000.

How To Listen To The Conference Call

Date: Oct 22, 2020

Time: 09:00 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/xey3oq98

Price Action

52-week high: $303.14

Company's 52-week low was at $124.53

Price action over last quarter: Up 8.28%

Company Description

West Pharmaceutical Services is a Pennsylvania-based medical supplies company that operates as a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West develops, manufactures, and distributes elastomer-based supplies for the containment and administration of injectable drugs, including basic equipment such as syringes, stoppers, and plungers, along with somewhat more complicated devices including auto-injectors and other self-injection platforms. The company reports in two segments: proprietary products (75% of 2019 sales) and contract-manufactured products (25%). The firm generates 56% of its revenue from international markets and 44% from the United States.